NEJM Takes Aim At Expensive Accelerated Approval Drugs Amid Congressional Drug Pricing Debate

Authors propose imposing penalties on drugmakers who don't start confirmatory trials shortly after accelerated approval and additional discounts for public payers; proposals could pick up steam among congressional democrats amid their renewed call for lower drug prices.

As the issue of drug pricing has continued to pick up steam across congressional user fee reauthorization hearings, a new series of drug pricing proposals could catch the attention of lawmakers seeking to explore options beyond the generic drugs route to lowering prices.

Writing in the New England Journal of Medicine May 25, University of Pittsburgh School of Medicine Professor Walid Gellad and...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Approval Standards

More from Pathways & Standards